Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study

Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study

The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in the pathophysiology of Charcot neuroarthropat...

Full description

Bibliographic Details
Main Authors: Dured Dardari, Claire Thomas, Francois-Xavier Laborne, Caroline Tourte, Elodie Henry, Megane Erblang, Stéphanie Bourdon, Alfred Penfornis, Philippe Lopes
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Medicina
Subjects:
diabetes
Charcot neuroarthropathy
receptor activator of nuclear factor-kappa B ligand (RANKL)
osteoprotegerin (OPG)
HbA1c
Online Access:https://www.mdpi.com/1648-9144/58/4/555

Internet

https://www.mdpi.com/1648-9144/58/4/555

Similar Items